This approval will enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.
Triphendiol (NV-196) is an investigational drug in the Marshall Edwards oncology drug pipeline, currently being developed as an orally-delivered chemosensitizing agent, intended for use in conjunction with standard chemotoxic anticancer drugs for the treatment of late stage pancreatic cancer, cholangiocarcinoma, and melanoma.